FAIRFIELD, N.J., May 21 /PRNewswire-FirstCall/ -- Bradley Pharmaceuticals, Inc. today announced that Daniel Glassman, President and CEO, will participate in The Robins Group Emerging Opportunities Investment Conference being held at The University Club in New York City on May 24, 2007. Mr. Glassman is scheduled to present at 9:00 a.m. EDT.
The presentation will be webcast live and can be accessed by visiting www.bradpharm.com and clicking on Calendar of Events or by clicking on http://www.investorcalendar.com/CEPage.asp?ID=117096.
It is recommended that listeners log on 15 minutes early in order to register. For those unable to participate during the live webcast, an archive version of the presentation will be available for 30 days beginning 1:00 p.m. EDT on May 24, 2007.
Please visit Bradley Pharmaceuticals web site at: www.bradpharm.com.
Bradley Pharmaceuticals, Inc. was founded in 1985 as a specialty pharmaceutical company and markets to niche physician specialties in the U.S. and international markets. Bradley’s success is based upon its core strengths in marketing and sales which enables the company to Commercialize brands that fill unmet patient and physician needs; Develop new products through life cycle management; and In-License phase II and phase III drugs with long-term intellectual property protection that upon approval leverage Bradley’s marketing and sales expertise to increase shareholder value. Bradley Pharmaceuticals is comprised of Doak Dermatologics, specializing in therapies for dermatology and podiatry; Kenwood Therapeutics, providing gastroenterology, OB/GYN, respiratory and other internal medicine brands; and A. Aarons, which markets authorized generic versions of Doak and Kenwood therapies.
Important announcements:
Bradley Pharmaceuticals will present at the Banc of America Securities Health Care Conference 2007 to be held at The Four Seasons Hotel in Las Vegas, Nevada, May 30, 2007.
Bradley Pharmaceuticals will present at the FTN Midwest Securities Health Care Conference 2007, to be held at the Four Seasons Hotel in New York, NY, June 5, 2007.
Bradley Pharmaceuticals common stock is listed on the NYSE under the symbol BDY.
Safe Harbor for Forward-Looking Statements
This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements that address activities, events or developments that Bradley expects, believes or anticipates will or may occur in the future, such as Bradley’s plans to in-license, develop and launch new and enhanced products with long-term intellectual property protection or other significant barriers to market entry, sales and earnings estimates, other predictions of financial performance, timing of payments on indebtedness, launches by Bradley of new products, market acceptance of Bradley’s products, and the achievement of initiatives to enhance corporate governance and long-term shareholder value. Forward-looking statements are based on Bradley’s experience and perception of current conditions, trends, expected future developments and other factors it believes are appropriate under the circumstances and are subject to numerous risks and uncertainties, many of which are beyond Bradley’s control. These risks and uncertainties include Bradley’s ability to: launch VEREGEN(TM) at the end of 2007 and ELESTRIN(TM) at the end of the second quarter 2007; predict the safety and efficacy of these products in a commercial setting; estimate sales; maintain adequate inventory levels; implement its returns and inventory optimization plan timely, if at all; reduce product returns; comply with the restrictive covenants under its credit facility; refinance its credit facility; access the capital markets on attractive terms or at all; favorably resolve the pending SEC informal inquiry; maintain or increase sales of its products; or effectively react to other risks and uncertainties described from time to time in Bradley’s SEC filings, such as fluctuation of quarterly financial results, estimation of product returns, chargebacks, rebates and allowances, concentration of customers, reliance on third party manufacturers and suppliers, litigation or other proceedings (including the pending class action and shareholder derivative lawsuits), government regulation and stock price volatility. Further, Bradley cannot accurately predict the impact on its business of the approval, introduction, or expansion by competitors of generic or therapeutically equivalent or comparable versions of Bradley’s products or of any other competing products. In addition, actual results may differ materially from those projected. Bradley undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
Bradley Pharmaceuticals, Inc.
CONTACT: Cecelia C. Heer, Investor Relations of Bradley Pharmaceuticals,Inc., +1-973-882-1505, ext. 252
Web site: http://www.bradpharm.com//
